DAVIDE CAMPARI-MILANO NV (CPR.MI) Stock Fundamental Analysis
BIT:CPR - Euronext Milan - NL0015435975 - Common Stock - Currency: EUR
Overall CPR gets a fundamental rating of 4 out of 10. We evaluated CPR against 27 industry peers in the Beverages industry. CPR has only an average score on both its financial health and profitability. CPR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CPR had positive earnings in the past year.
In the past year CPR had a positive cash flow from operations.
CPR had positive earnings in each of the past 5 years.
In the past 5 years CPR always reported a positive cash flow from operatings.
1.2 Ratios
CPR's Return On Assets of 2.38% is in line compared to the rest of the industry. CPR outperforms 40.74% of its industry peers.
Looking at the Return On Equity, with a value of 5.23%, CPR is in line with its industry, outperforming 40.74% of the companies in the same industry.
The Return On Invested Capital of CPR (6.63%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for CPR is in line with the industry average of 8.68%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.38% | ||
| ROE | 5.23% | ||
| ROIC | 6.63% |
ROA(3y)4.29%
ROA(5y)4.52%
ROE(3y)9.66%
ROE(5y)10.08%
ROIC(3y)7.66%
ROIC(5y)7.27%
1.3 Margins
CPR has a Profit Margin of 6.57%. This is comparable to the rest of the industry: CPR outperforms 44.44% of its industry peers.
CPR's Profit Margin has declined in the last couple of years.
CPR has a Operating Margin (21.32%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of CPR has remained more or less at the same level.
CPR has a Gross Margin of 57.55%. This is in the better half of the industry: CPR outperforms 70.37% of its industry peers.
CPR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.32% | ||
| PM (TTM) | 6.57% | ||
| GM | 57.55% |
OM growth 3Y3.05%
OM growth 5Y-0.43%
PM growth 3Y-20.58%
PM growth 5Y-17.07%
GM growth 3Y-1.21%
GM growth 5Y-1.11%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPR is still creating some value.
Compared to 1 year ago, CPR has more shares outstanding
Compared to 5 years ago, CPR has more shares outstanding
CPR has about the same debt/assets ratio as last year.
2.2 Solvency
CPR has an Altman-Z score of 2.40. This is not the best score and indicates that CPR is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of CPR (2.40) is better than 62.96% of its industry peers.
CPR has a debt to FCF ratio of 13.61. This is a negative value and a sign of low solvency as CPR would need 13.61 years to pay back of all of its debts.
CPR has a Debt to FCF ratio (13.61) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.66 indicates that CPR is somewhat dependend on debt financing.
With a decent Debt to Equity ratio value of 0.66, CPR is doing good in the industry, outperforming 70.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 13.61 | ||
| Altman-Z | 2.4 |
ROIC/WACC0.95
WACC6.96%
2.3 Liquidity
CPR has a Current Ratio of 2.37. This indicates that CPR is financially healthy and has no problem in meeting its short term obligations.
CPR has a Current ratio of 2.37. This is in the better half of the industry: CPR outperforms 77.78% of its industry peers.
A Quick Ratio of 0.99 indicates that CPR may have some problems paying its short term obligations.
The Quick ratio of CPR (0.99) is better than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.37 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for CPR have decreased strongly by -39.43% in the last year.
Measured over the past years, CPR shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.12% on average per year.
The Revenue has been growing slightly by 5.18% in the past year.
Measured over the past years, CPR shows a quite strong growth in Revenue. The Revenue has been growing by 10.75% on average per year.
EPS 1Y (TTM)-39.43%
EPS 3Y-11.44%
EPS 5Y-8.12%
EPS Q2Q%-109.15%
Revenue 1Y (TTM)5.18%
Revenue growth 3Y12.21%
Revenue growth 5Y10.75%
Sales Q2Q%-45.74%
3.2 Future
The Earnings Per Share is expected to grow by 8.10% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.93% on average over the next years.
EPS Next Y1.31%
EPS Next 2Y6.65%
EPS Next 3Y8.05%
EPS Next 5Y8.1%
Revenue Next Year5.14%
Revenue Next 2Y5.03%
Revenue Next 3Y5.27%
Revenue Next 5Y4.93%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 31.60, the valuation of CPR can be described as expensive.
Based on the Price/Earnings ratio, CPR is valued a bit more expensive than 70.37% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.35. CPR is around the same levels.
With a Price/Forward Earnings ratio of 18.91, CPR is valued on the expensive side.
CPR's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CPR is more expensive than 66.67% of the companies in the same industry.
CPR's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.20.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.6 | ||
| Fwd PE | 18.91 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPR is valued a bit more expensive than 62.96% of the companies in the same industry.
CPR's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. CPR is more expensive than 62.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.29 | ||
| EV/EBITDA | 12.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CPR does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)24.13
PEG (5Y)N/A
EPS Next 2Y6.65%
EPS Next 3Y8.05%
5. Dividend
5.1 Amount
CPR has a Yearly Dividend Yield of 1.14%.
Compared to an average industry Dividend Yield of 2.78, CPR is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.40, CPR's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.14% |
5.2 History
The dividend of CPR decreases each year by -2.80%.
Dividend Growth(5Y)-2.8%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
CPR pays out 38.74% of its income as dividend. This is a sustainable payout ratio.
DP38.74%
EPS Next 2Y6.65%
EPS Next 3Y8.05%
BIT:CPR (5/27/2025, 7:00:00 PM)
5.688
+0.01 (+0.14%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryBeverages
Earnings (Last)
Earnings (Next)
Inst Owners23.33%
Inst Owner ChangeN/A
Ins Owners52.32%
Ins Owner ChangeN/A
Market Cap7.00B
Analysts70.71
Price Target7.09 (24.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.14% |
Yearly Dividend0.04
Dividend Growth(5Y)-2.8%
DP38.74%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.14%
PT rev (3m)-10.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-5.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-0.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.6 | ||
| Fwd PE | 18.91 | ||
| P/S | 2.28 | ||
| P/FCF | 33.29 | ||
| P/OCF | 10.45 | ||
| P/B | 1.82 | ||
| P/tB | 153.58 | ||
| EV/EBITDA | 12.56 |
EPS(TTM)0.18
EY3.16%
EPS(NY)0.3
Fwd EY5.29%
FCF(TTM)0.17
FCFY3%
OCF(TTM)0.54
OCFY9.57%
SpS2.49
BVpS3.13
TBVpS0.04
PEG (NY)24.13
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.38% | ||
| ROE | 5.23% | ||
| ROCE | 9.04% | ||
| ROIC | 6.63% | ||
| ROICexc | 6.65% | ||
| ROICexgc | 14.08% | ||
| OM | 21.32% | ||
| PM (TTM) | 6.57% | ||
| GM | 57.55% | ||
| FCFM | 6.85% |
ROA(3y)4.29%
ROA(5y)4.52%
ROE(3y)9.66%
ROE(5y)10.08%
ROIC(3y)7.66%
ROIC(5y)7.27%
ROICexc(3y)8.52%
ROICexc(5y)8.34%
ROICexgc(3y)23.37%
ROICexgc(5y)25.9%
ROCE(3y)10.45%
ROCE(5y)9.91%
ROICexcg growth 3Y-20.45%
ROICexcg growth 5Y-21.73%
ROICexc growth 3Y-7.67%
ROICexc growth 5Y-5.91%
OM growth 3Y3.05%
OM growth 5Y-0.43%
PM growth 3Y-20.58%
PM growth 5Y-17.07%
GM growth 3Y-1.21%
GM growth 5Y-1.11%
F-Score4
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 13.61 | ||
| Debt/EBITDA | 3.27 | ||
| Cap/Depr | 360.3% | ||
| Cap/Sales | 14.99% | ||
| Interest Coverage | 6.98 | ||
| Cash Conversion | 85.73% | ||
| Profit Quality | 104.37% | ||
| Current Ratio | 2.37 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 2.4 |
F-Score4
WACC6.96%
ROIC/WACC0.95
Cap/Depr(3y)346.34%
Cap/Depr(5y)266.11%
Cap/Sales(3y)12.99%
Cap/Sales(5y)10.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.43%
EPS 3Y-11.44%
EPS 5Y-8.12%
EPS Q2Q%-109.15%
EPS Next Y1.31%
EPS Next 2Y6.65%
EPS Next 3Y8.05%
EPS Next 5Y8.1%
Revenue 1Y (TTM)5.18%
Revenue growth 3Y12.21%
Revenue growth 5Y10.75%
Sales Q2Q%-45.74%
Revenue Next Year5.14%
Revenue Next 2Y5.03%
Revenue Next 3Y5.27%
Revenue Next 5Y4.93%
EBIT growth 1Y6.39%
EBIT growth 3Y15.63%
EBIT growth 5Y10.27%
EBIT Next Year23.05%
EBIT Next 3Y13.08%
EBIT Next 5Y11.25%
FCF growth 1Y232.49%
FCF growth 3Y-14.61%
FCF growth 5Y-4.94%
OCF growth 1Y328.44%
OCF growth 3Y11.5%
OCF growth 5Y13.06%